I understand everyone’s thought that FDA is biased toward companies that pay them for expedited review, however, I think there are several misconceptions and also poor structure setup that attribute to this notion that “big pharma” or major corporations run…   Read more»

[quote data-userid=”35393″ data-postid=”24219″] One thing that I think could fit under this category are certain diagnostic tests that are currently listed as Class III. I think over time, some of these tests should be reconsidered to join Class II. This…   Read more»

From my experience in industry I think making as little claims as possible is the ideal way to go. Anything that doesn’t support the main claim or function of a product should be avoided and wording is key. For example,…   Read more»